A detailed history of Strs Ohio transactions in Castle Biosciences Inc stock. As of the latest transaction made, Strs Ohio holds 19,100 shares of CSTL stock, worth $588,853. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,100
Previous 25,800 25.97%
Holding current value
$588,853
Previous $561,000 3.03%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$17.4 - $31.47 $116,579 - $210,849
-6,700 Reduced 25.97%
19,100 $544,000
Q2 2024

Aug 05, 2024

BUY
$18.84 - $24.94 $58,404 - $77,314
3,100 Added 13.66%
25,800 $561,000
Q1 2024

May 13, 2024

SELL
$18.06 - $25.3 $25,284 - $35,420
-1,400 Reduced 5.81%
22,700 $502,000
Q4 2023

Jan 30, 2024

SELL
$12.19 - $22.43 $48,760 - $89,720
-4,000 Reduced 14.23%
24,100 $520,000
Q2 2023

Jul 31, 2023

BUY
$11.66 - $26.0 $11,660 - $26,000
1,000 Added 3.69%
28,100 $385,000
Q1 2023

Aug 02, 2023

SELL
$19.47 - $28.49 $19,470 - $28,490
-1,000 Reduced 3.56%
27,100 $615,000
Q1 2023

Apr 27, 2023

BUY
$19.47 - $28.49 $130,448 - $190,883
6,700 Added 32.84%
27,100 $615,000
Q2 2022

Jul 25, 2022

BUY
$16.0 - $45.99 $281,600 - $809,424
17,600 Added 628.57%
20,400 $447,000
Q3 2021

Oct 22, 2021

SELL
$60.13 - $77.6 $264,572 - $341,440
-4,400 Reduced 61.11%
2,800 $186,000
Q2 2021

Jul 26, 2021

SELL
$50.07 - $76.78 $275,385 - $422,290
-5,500 Reduced 43.31%
7,200 $527,000
Q1 2021

Apr 23, 2021

SELL
$58.92 - $97.33 $11,784 - $19,466
-200 Reduced 1.55%
12,700 $869,000
Q3 2020

Dec 14, 2020

BUY
$38.47 - $52.03 $457,793 - $619,157
11,900 Added 1190.0%
12,900 $663,000
Q3 2019

Oct 21, 2019

BUY
$18.09 - $27.92 $18,090 - $27,920
1,000 New
1,000 $18,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $811M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.